RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition

Core Viewpoint - RAPT Therapeutics has agreed to be acquired by GSK in a deal valued at approximately $2.2 billion, leading to a significant increase in RAPT's share price [1] Company Summary - RAPT Therapeutics is a biopharmaceutical company that focuses on developing therapies for cancer and other serious diseases [1] - The acquisition by GSK represents a strategic move to enhance GSK's portfolio in the biopharmaceutical sector [1] Financial Summary - The acquisition deal is valued at around $2.2 billion, indicating a strong market interest and valuation for RAPT Therapeutics [1]